Media.Player

The Integrin Activation Interface

Technology Benefits

Can be used with high specificity to modulate the talin-integrin beta-sub3 interaction without the side effects that may occur with presently available therapeutic agents and methods. Offers a new screening method to detect agents that block integrin beta-sub3 activation, as well as a method for screening alterations in talin function. Available as DNA constructs and vectors.

Detailed Technology Description

Researchers at UC San Diego have elucidated a novel molecular interface between two proteins, talin and the membrane proximal portion of the beta-sub3 integrin domain. Specifically, the research team has identified and validated a specific structural target that was previously unknown and could aid in the design of therapeutics to block integrin activation. This discovery may enable the engineering of cells with defects in the activation of multiple classes of integrins and offers a new target for therapeutic intervention to treat diseases and conditions such as inflammation, autoimmune diseases, heart disease (including myocardial infarction), and cancer.

Supplementary Information

Patent Number: US8530621B2
Application Number: US2009523037A
Inventor: Ginsberg, Mark | Partridge, Anthony William | Campbell, Iain | Wegener, Kate Louise
Priority Date: 12 Jan 2007
Priority Number: US8530621B2
Application Date: 26 Apr 2010
Publication Date: 10 Sep 2013
IPC Current: A61K003804
US Class: 530324
Assignee Applicant: The Regents of the University of California
Title: Combined preparation of a thiazide diuretic and a loop diuretic
Usefulness: Combined preparation of a thiazide diuretic and a loop diuretic
Summary: The isolated complex is useful for blocking integrin β 3 activation for treating a condition or disease e.g. myocardial infarction, tumor metastasis, and rheumatoid arthritis; and for screening to detect an agent that blocks integrin β 3 activation (all claimed). It is also useful for screening for alteration in talin function.
Novelty: New isolated complex comprising a structural interface between talin and integrin beta-3, useful for blocking integrin beta-3 activation for treating a condition e.g. myocardial infarction, tumor metastasis, and rheumatoid arthritis

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

Application No.

8530621

Others

Intellectual Property Info

This invention is available for licensing. See international patent application, published 24-July-2008 (2008/051016).

Related Materials

Wegener KL, AW Partridge, J Han, AR Pickford, RC Liddington, MH Ginsberg, ID Campbell (2007) Structural Basis of Integrin Activation by Talin, Cell, 128:(1)171-182.

Tech ID/UC Case

19150/2007-053-0

Related Cases

2007-053-0

*Abstract

Integrins are found throughout the animal kingdom where they play important roles in cell adhesion, migration, proliferation, and survival. In humans, integrins play critical roles in development. Aberrant activation is implicated in several disease states, including cancer and heart disease. Thus, drugs aimed at disrupting this specific interaction could lead to therapies for these conditions.

*IP Issue Date

Sep 10, 2013

*Principal Investigator

Name: Iain Campbell

Department:

Name: Mark Ginsberg

Department:

Name: Anthony Partridge

Department:

Name: Kate Wegener

Department:

Country/Region

USA